Arch Biopartners: AB569 Successfully Completes Pre-Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies

TORONTO, CANADA--(Marketwired - Sept. 17, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced AB569, the Company's drug candidate for treating pulmonary Pseudomonas aeruginosa ( P. aeruginosa) infections, has successfully completed pre-clinical in vivo and in vitro validation studies.

In all studies, AB569 has demonstrated significant efficacy against P. aeruginosa . This includes a recent study involving a chronic pulmonary infection model in mice.

The Arch team believes these results provide the scientific rationale for pursuing a human trial to test the safety and efficacy of AB569 for cystic fibrosis (CF) patients whose airways are chronically infected with P. aeruginosa . In this regard, Arch management is currently assessing the appropriate toxicology and regulatory path to the first human trial for AB569.

In the coming months, the scientists involved in the above studies intend to disclose the details of their results in an academic publication.

The Clinical Need for a New Treatment for P. aeruginosa

P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have CF or chronic obstructive pulmonary disease (COPD). It is also a common cause of pneumonia.

There are approximately 40,000 CF patients and over 14 million individuals diagnosed with COPD in the United States. It is estimated that 2 to 3 million people in the USA are diagnosed with pneumonia each year.

In particular, the mucoid form of P. aeruginosa , often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa , their overall lung function precipitously declines, resulting in a poor prognosis.

Thus, there is an urgent clinical need for the development of novel effective treatments in this area. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa infections that are resistant to traditional antibiotics.

Cystic Fibrosis

CF is an autosomal recessive genetic disease that causes abnormalities of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is a critical regulator of sweat, digestive fluids, and mucus production.

CF patients are predisposed to lung infections due to abnormal mucus production in the lungs and airways. P. aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.

About Arch Biopartners

Arch Biopartners is a portfolio-based biotechnology company established to develop new products and technology for unmet medical needs. The Company's portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory P. aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.

Arch has also been developing its peptide-solid surface interface with the objective of reducing corrosion, biofilm formation and improving biocompatibility of various metals and plastics.

For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com .

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Arch Biopartners, Inc. Richard Muruve (647) 428 7031 info@archbiopartners.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 158

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Fundraising Initiative by Robin Hood for NYC

Updated Category News Views 459

Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...

Continue Reading
Newell Brands Faces Analyst Downgrades After Earnings Release

Updated Category News Views 179

Newell Brands' Earnings Report: An Overview Newell Brands Inc. (NASDAQ: NWL) has recently reported its second-quarter earnings, revealing a mixed performance that has caught the attention of investors and analysts alike. Highlighting both earnings that met expectations and revenues that fell short, the company’s report has prompted analysts to adjust their projections...

Continue Reading
Smart Lock Market Projected Growth to US$ 16.47 Billion

Updated Category News Views 210

Smart Lock Market Value and Forecast The global smart lock market is experiencing significant growth, currently valued at approximately US$ 6.76 billion in 2024. Projections indicate that it will reach US$ 16.47 billion by 2033, showcasing a robust annual growth rate (CAGR) of 10.4% during this period. This growth can be attributed to a surge in consumer awareness...

Continue Reading
Analyzing UnitedHealth Group's Current Market Movement and Outlook

Updated Category News Views 191

Understanding the Options Activity of UnitedHealth Group In recent trading sessions, there has been notable bearish activity surrounding UnitedHealth Group (NYSE: UNH). High-profile investors seem to be indicating cautious sentiment toward this health insurance giant, which warrants the attention of retail traders. Insights from Recent Options Trading The trading data...

Continue Reading
Stan Bernard Steps Up as Zurich's New Head of Industry Practices

Updated Category News Views 261

Stan Bernard is Promoted to Lead Industry Practices at Zurich In an exciting development for Zurich North America, Stan Bernard has been appointed as the new Head of Industry Practices for the U.S. Middle Market. This significant promotion comes as Bernard takes over from Lynn Zeitler, who is retiring after an impressive 31-year career with the company. Bernard’s ascent...

Continue Reading